Taguchi T, Koyama H, Yayoi K, Wada T, Takatsuka Y, Sonoo H, Morimoto K, Tominaga T, Abe R, Enomoto K
Japan Society for Cancer Chemotherapy, Dept. of Surgery, Center for Adult Diseases, Osaka.
Gan To Kagaku Ryoho. 1995 Mar;22(4):495-508.
Efficacy and safety of long-term treatment with an LH-RH agonist, TAP-144-SR were studied in premenopausal patients with advanced or recurrent breast cancer. The drug was given sc every 4 week at the dose of 3.75 or 7.5mg. The best objective response rates were 37.0% (17/46) in 3.75mg group, 30.6% (15/49) in 7.5mg group, respectively. The median duration of 12 PR patients in 3.75mg group was 280 (range: 84-830+) days. Serum estradiol level was maintained at < 30pg/ml in most patients given 3.75mg or 7.5mg as scheduled. There was no adverse reactions specific to the longterm administration subsequent to the foregoing 12-week administration study in both dose groups. In conclusion, TAP-144-SR is expected to be one of the first line therapies for patients with premenopausal breast cancer.
在绝经前晚期或复发性乳腺癌患者中研究了促黄体生成激素释放激素（LH-RH）激动剂TAP-144-SR的长期治疗效果和安全性。该药物每4周皮下注射一次，剂量为3.75毫克或7.5毫克。3.75毫克组的最佳客观缓解率为37.0%（17/46），7.5毫克组为30.6%（15/49）。3.75毫克组12例部分缓解（PR）患者的中位缓解持续时间为280天（范围：84 - 830 +天）。在按计划给予3.75毫克或7.5毫克药物的大多数患者中，血清雌二醇水平维持在<30皮克/毫升。在上述两个剂量组的12周给药研究之后，长期给药没有特定的不良反应。总之，TAP-144-SR有望成为绝经前乳腺癌患者的一线治疗方法之一。
